Cargando…

Impact of medication adherence on the efficacy of Baroreflex activation therapy

Therapy adherence significantly determines the success of antihypertensive therapy, especially in patients with resistant hypertension. Our study investigates the impact of drug adherence on the efficacy of Baroreflex‐activation‐therapy (BAT). In this retrospective analysis, the authors measured blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Ann‐Kathrin C., Müller, Dieter, Born, Ellen, Mühlhaus, Maria, Lüders, Stephan, Wallbach, Manuel, Koziolek, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380177/
https://www.ncbi.nlm.nih.gov/pubmed/35870124
http://dx.doi.org/10.1111/jch.14540
_version_ 1784768829780393984
author Schäfer, Ann‐Kathrin C.
Müller, Dieter
Born, Ellen
Mühlhaus, Maria
Lüders, Stephan
Wallbach, Manuel
Koziolek, Michael J.
author_facet Schäfer, Ann‐Kathrin C.
Müller, Dieter
Born, Ellen
Mühlhaus, Maria
Lüders, Stephan
Wallbach, Manuel
Koziolek, Michael J.
author_sort Schäfer, Ann‐Kathrin C.
collection PubMed
description Therapy adherence significantly determines the success of antihypertensive therapy, especially in patients with resistant hypertension. Our study investigates the impact of drug adherence on the efficacy of Baroreflex‐activation‐therapy (BAT). In this retrospective analysis, the authors measured blood pressure (BP) and antihypertensive medication adherence (by gas chromatography‐mass spectrometry [GC‐MS] urine analysis) before and 6 months after BAT initiation. Adherence was defined as detection of ≥80% intake of prescribed medication at the time of follow‐up. Response to BAT was defined as BP drop ≥5 mmHg in systolic 24 h‐ambulatory BP (ABP) after 6 months. Overall patients (n = 38) median medication adherence was low, but rose from 60% (IQR 25%–100%) to 75% (IQR 38%–100%; p = .0194). After 6 months of BAT, mean systolic and diastolic office BP (‐21 ± 25 mmHg and ‐9 ± 15 mmHg; p < .0001 and .0004) as well as 24 h‐ABP dropped significantly (‐9 ± 17 mmHg and ‐5 ± 12 mmHg; p = .0049 and .0280). After 6 months of BAT, 21 patients (60%) could be classified as responders. There was neither significant difference in mean office systolic (‐21 ± 23 mmHg vs. ‐21 ± 28 mmHg; p = .9581) nor in 24 h‐systolic ABP decrease (‐11 ± 19 mmHg vs. ‐7 ± 15 mmHg; p = .4450) comparing adherent and non‐adherent patients. Whereas Antihypertensive Therapeutic Index (ATI) was unchanged in non‐responders, it significantly decreased in responders (from 50 ± 16 to 46 ± 16; p = .0477). These data are the first to show that BAT‐initiation leads to a clear BP reduction independently of patients´ medication adherence. Response to BAT is associated with a significant lowering of ATI, which might contribute to an underestimation of BAT efficacy.
format Online
Article
Text
id pubmed-9380177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93801772022-08-19 Impact of medication adherence on the efficacy of Baroreflex activation therapy Schäfer, Ann‐Kathrin C. Müller, Dieter Born, Ellen Mühlhaus, Maria Lüders, Stephan Wallbach, Manuel Koziolek, Michael J. J Clin Hypertens (Greenwich) Medication Adherence Therapy adherence significantly determines the success of antihypertensive therapy, especially in patients with resistant hypertension. Our study investigates the impact of drug adherence on the efficacy of Baroreflex‐activation‐therapy (BAT). In this retrospective analysis, the authors measured blood pressure (BP) and antihypertensive medication adherence (by gas chromatography‐mass spectrometry [GC‐MS] urine analysis) before and 6 months after BAT initiation. Adherence was defined as detection of ≥80% intake of prescribed medication at the time of follow‐up. Response to BAT was defined as BP drop ≥5 mmHg in systolic 24 h‐ambulatory BP (ABP) after 6 months. Overall patients (n = 38) median medication adherence was low, but rose from 60% (IQR 25%–100%) to 75% (IQR 38%–100%; p = .0194). After 6 months of BAT, mean systolic and diastolic office BP (‐21 ± 25 mmHg and ‐9 ± 15 mmHg; p < .0001 and .0004) as well as 24 h‐ABP dropped significantly (‐9 ± 17 mmHg and ‐5 ± 12 mmHg; p = .0049 and .0280). After 6 months of BAT, 21 patients (60%) could be classified as responders. There was neither significant difference in mean office systolic (‐21 ± 23 mmHg vs. ‐21 ± 28 mmHg; p = .9581) nor in 24 h‐systolic ABP decrease (‐11 ± 19 mmHg vs. ‐7 ± 15 mmHg; p = .4450) comparing adherent and non‐adherent patients. Whereas Antihypertensive Therapeutic Index (ATI) was unchanged in non‐responders, it significantly decreased in responders (from 50 ± 16 to 46 ± 16; p = .0477). These data are the first to show that BAT‐initiation leads to a clear BP reduction independently of patients´ medication adherence. Response to BAT is associated with a significant lowering of ATI, which might contribute to an underestimation of BAT efficacy. John Wiley and Sons Inc. 2022-07-23 /pmc/articles/PMC9380177/ /pubmed/35870124 http://dx.doi.org/10.1111/jch.14540 Text en © 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Medication Adherence
Schäfer, Ann‐Kathrin C.
Müller, Dieter
Born, Ellen
Mühlhaus, Maria
Lüders, Stephan
Wallbach, Manuel
Koziolek, Michael J.
Impact of medication adherence on the efficacy of Baroreflex activation therapy
title Impact of medication adherence on the efficacy of Baroreflex activation therapy
title_full Impact of medication adherence on the efficacy of Baroreflex activation therapy
title_fullStr Impact of medication adherence on the efficacy of Baroreflex activation therapy
title_full_unstemmed Impact of medication adherence on the efficacy of Baroreflex activation therapy
title_short Impact of medication adherence on the efficacy of Baroreflex activation therapy
title_sort impact of medication adherence on the efficacy of baroreflex activation therapy
topic Medication Adherence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380177/
https://www.ncbi.nlm.nih.gov/pubmed/35870124
http://dx.doi.org/10.1111/jch.14540
work_keys_str_mv AT schaferannkathrinc impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT mullerdieter impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT bornellen impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT muhlhausmaria impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT ludersstephan impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT wallbachmanuel impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy
AT koziolekmichaelj impactofmedicationadherenceontheefficacyofbaroreflexactivationtherapy